The numbers are stark. CAD 94.5 million. That’s the capital Jubilant DraxImage Inc., a subsidiary wholly owned by Jubilant Pharmova, is pouring into its Kirkland, Québec facility. The goal is simple but aggressive: double the manufacturing capacity for RUBY-FILL, their flagship radiopharmaceutical. This isn’t a marginal upgrade; it’s a structural expansion designed to match a customer base that has literally doubled over the last three years.
Who’s paying for it? Not entirely the company. The Government of Canada is chipping in CAD 23.8 million through the Strategic Response Fund’s innovation stream. For the rest of the pot, Jubilant is covering the costs to install state-of-the-art production equipment. Harsh Singh, CEO of Jubilant Radiopharma, framed it as a commitment to securing high-value jobs in Quebec and ensuring a reliable global supply. “This investment recognises Jubilant Radiopharma’s innovation capabilities in Nuclear Medicine,” Singh said.
The product itself is niche but critical. RUBY-FILL enables on-site production of Rubidium-82, a radionuclide used for cardiac PET imaging. It helps clinicians spot coronary artery disease with precision. The Kirkland site is unique—it’s the only place in Canada producing these specific product categories. Beyond RUBY-FILL, the facility handles a broader portfolio spanning Technetium-99m for SPECT imaging and Iodine-131 for treating thyroid cancer and neuroblastoma. Expansion here means expanded reach across cardiology, oncology, and nuclear medicine.
On the exchange, the mood was less celebratory. Jubilant Pharmova shares closed at ₹936.15 on the BSE, down ₹38.10, or 3.91%. The dip comes fresh after the company reported a 45% fall in Q1 profit due to margin pressure. Investors seem to be weighing the long-term capacity benefits against the near-term earnings squeeze. The US CMO facility also recently received a 'Voluntary Action Indicated' classification, adding another layer of scrutiny to the company’s operational compliance.
So, what’s next? The expansion is a bet on sustained global demand for precision medicine diagnostics. With the customer base already doubling, the capacity gap was becoming a bottleneck. By modernizing the Kirkland facility, Jubilant is positioning itself to capture that growth without risking supply chain fragility. Watch the next earnings release to see if the margin pressures ease or if the capex heavy-lifting drags on cash flow further.